Scientists hunt for clues in the blood to predict lung fibrosis outcomes
NCT ID NCT04016181
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study looks for biological markers in blood and lung samples from people with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. The goal is to find markers that can predict how the disease will progress and to group patients into subtypes. Researchers will follow about 800 participants over time to see which markers are linked to faster decline or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to predict disease progression and tailor treatment for people with lung fibrosis.
- What could go wrong
- This is an observational study, not a treatment trial. It may not find clear biomarkers, and results may not change care directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASBESTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI catch lung scarring that doctors might miss?
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can arm workouts boost oxygen use in lung disease?
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues